Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Verducatib Under Fed and Fasted Conditions
NCT03837964Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Feb 2019
- Primary completion
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of verducatib in bronchiectasis (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area under the concentration-time curve from time zero to the last quantifiable data point up to 264 hours and Maximum measured concentration in plasma up to 264 hours. Started Feb 2019; status: completed.
02
Drugs
verducatib
03
Conditions
bronchiectasis
Beyond the preview
Go deeper on NCT03837964.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03837964.